2027 ICD-10-CM Diagnosis Code D75.81Myelofibrosis
ICD-10-CM Codes›D50–D89›D70-D77›D75
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 19
- Chronic Condition
D75.81 is a billable ICD-10-CM diagnosis code for myelofibrosis. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 133 closely related codes. The code is a manifestation code that cannot be reported as the principal diagnosis. Coders also document this condition as congenital neutropenia, myelofibrosis, nephromegaly syndrome. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified hematologic conditions.
For Medicare Advantage risk adjustment, D75.81 maps to CMS-HCC Category 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) under the V28 model, adding a risk factor of about 1.798 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for D75.81.
Medicare Risk Adjustment (HCC)Billing
D75.81 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Congenital neutropenia, myelofibrosis, nephromegaly syndrome
- Hereditary thrombocytopenia with early-onset myelofibrosis
- Ischemic myelofibrosis
- Myelofibrosis
- Myelofibrosis caused by drug
- Myelofibrosis due to another disorder
- Neoplastic sequelae of disorders
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D75.81: its own notes plus those printed at D75 and Chapter 3. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Myelofibrosis NOS
- Secondary myelofibrosis NOS
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Code First
The underlying condition named in the note is sequenced before this code.
- the underlying disorder, such as:
- malignant neoplasm of breast (C50.-)
Use Additional Code
Add a second code, after this one, to fully describe the condition.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name D75.81, its category, or a range that includes it.
Excludes1 7
These codes carry an Excludes1 note naming D75.81: they are not reported together with it, unless the two conditions are unrelated.
- C94.4 Acute panmyelosis with myelofibrosismyelofibrosis NOS (D75.81)
- C94.4 Acute panmyelosis with myelofibrosissecondary myelofibrosis NOS (D75.81)
- D47.1 Chronic myeloproliferative diseasemyelofibrosis NOS (D75.81)
- D47.1 Chronic myeloproliferative diseasesecondary myelofibrosis NOS (D75.81)
- D61.82 Myelophthisismyelofibrosis NOS (D75.81)
- D61.82 Myelophthisissecondary myelofibrosis (D75.81)
- M85.8 Other specified disorders of bone density and structureosteosclerosis myelofibrosis (D75.81)
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) D64.9
myelofibrosis D75.81
Myelofibrosis D75.81
secondary D75.81
myelofibrosis D75.81
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Primary Myelofibrosis
a de novo myeloproliferation arising from an abnormal stem cell. it is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by cytokines arising from the abnormal clone.
Patient EducationClinical
Bone Marrow Diseases
Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D75.81 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D75.81Overview
What is the ICD-10 code for myelofibrosis?
The ICD-10-CM code for myelofibrosis is D75.81 (sometimes written as D7581). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is D75.81 (Other specified diseases of blood and blood-forming organs) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report myelofibrosis on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D75.81 group to?
On inpatient claims, myelofibrosis maps to MS-DRG 841, 821, 822, 825, 842, 824, 840, 820, 823, with relative weights from 0.9948 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.
Is D75.81 a CC or MCC?
CMS lists D75.81 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 133 closely related codes in its exclusion list.
Can D75.81 be a principal diagnosis?
No. This is a manifestation code: myelofibrosis describes the manifestation of an underlying disease rather than the disease itself, so the underlying condition is sequenced first.
What HCC is D75.81?
D75.81 (myelofibrosis) maps to CMS-HCC Category 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers), commonly written as HCC 19, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 46 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 16.
Does D75.81 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D75.81 adds a risk adjustment factor of about 1.798 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.957 to 1.989 depending on the payment segment). A more severe related category (HCC 17 and HCC 18) supersedes it when both are reported. See the full factor table on the HCC 19 category page.
